➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

Litigation Details for Coherus Biosciences, Inc. v. Amgen Inc. (D. Del. 2019)

Email this page to a colleague

« Back to Dashboard

Biologic Drugs cited in Coherus Biosciences, Inc. v. Amgen Inc.
The biologic drug covered by the patents cited in this case is ⤷  Try it Free .

Details for Coherus Biosciences, Inc. v. Amgen Inc. (D. Del. 2019)

Date Filed Document No. Description Snippet Link To Document
2019-01-23 1 Complaint United States Patent Nos. 10,155,039 (“the ’039 patent”), 10,159,732 (“the ’732 patent”), and 10,159,…and continues to infringe the ’039 patent, ’732 patent, and ’733 patent; B) A judgment permanently…further infringement of the ’039 patent, ’732 patent, and ’733 patent; C) A judgment awarding…Amgen’s infringement of the ’039 patent, ’732 patent, and ’733 patent was deliberate and willful; …10,159,733 (“the ’733 patent”) under the Patent Laws of the United States, 35 U.S.C. § 1 et seq. External link to document
2019-06-24 18 Answer to Counterclaim The Patents-In-Suit 112. U.S. Patent No. 10,155,039 (“the ’039 patent”), titled “Stable…Non-Infringement and Invalidity of U.S. Patent No. 10,155,039 117. Amgen restates and incorporates… U.S. Patent No. 9,114,166 (the “’166 patent”), U.S. Patent No. 8,916,157 (the “’157 patent”), and…Asserted Patents, for example, U.S. Patent No. 9,272,041 (the “’041 patent”) and U.S. Patent No. …and ’714 patents are more relevant than the ’166 patent, the ’157 patent, and the ’583 patent to the External link to document
2019-01-23 3 Patent/Trademark Report to Commissioner Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 10,155,039; US 10,159,732; US… 26 November 2019 1:19-cv-00139 830 Patent Plaintiff District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.